ライフサイエンスコーパス: bradykinin receptor

1 scle mechanism independent of an endothelial bradykinin receptor.

2 um channels in sensory neurons by activating bradykinin receptors.

3 activation but attenuating those mediated by bradykinin receptors.

4 e mediated by bradykinin acting on B1 and B2 bradykinin receptors.

5 to produce IL-12 through activation of B(2) bradykinin receptors.

6 res kallikrein activity but does not involve bradykinin receptors.

7 for the interaction of the kinins with human bradykinin receptor 1 (B1) using site-directed mutagenes

8 I/D) angiotensin-converting enzyme (ACE) and bradykinin receptor (+9/-9) genotypes were identified in

9 The B2 bradykinin receptor, a seven-helix transmembrane recepto

10 ASIC1a activity is independent of opioid or bradykinin receptor activation but is prevented in the p

11 P2Y(2)-Rs because it was mimicked by apical bradykinin receptor activation, and it did not result fr

12 duced VEGF secretion was dependent on the B2 bradykinin receptor, activation of protein kinase C, and

13 Similarly, pretreatment with bradykinin receptor agonists inhibited IL-8-induced neut

14 culum; estimation of the distribution of the bradykinin receptor along the surface of a neuronal cell

15 Absence of the bradykinin receptors also enhances the diabetes-associat

16 o promote pain through its agonist action at bradykinin receptors and suggest new avenues for therape

17 smic reticulum calcium ATPase (SERCA) pumps, bradykinin receptors, and ER] were based on 3D confocal

18 Bradykinin receptor antagonism did not affect the mean a

19 , neutralizing antibody to prekallikrein and bradykinin receptor antagonism.

20 kinin receptor antagonist HOE 140 and the B1 bradykinin receptor antagonist des-Arg9[Leu8]bradykinin

21 .8 microg/min) in 24 smokers pretreated with bradykinin receptor antagonist HOE 140 (100 microg/kg in

22 The B2 bradykinin receptor antagonist HOE 140 and the B1 bradyk

23 prevented by concomitant treatment with the bradykinin receptor antagonist icatibant.

24 Recently, icatibant, a bradykinin receptor antagonist, has been used to success

25 tudy were to determine the doses of B9340, a bradykinin receptor antagonist, that inhibit vasodilatat

26 In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 1

27 Bradykinin receptor antagonists may be of benefit in tre

28 disrupts signaling at P2Y receptors and that bradykinin receptors are not prelocalized to cholesterol

29 dels by monitoring the association of type 2 bradykinin receptor (B(2)R) and the Galpha(q)/Gbetagamma

30 etylcholine receptor (M(1)AchR) and the B(2) bradykinin receptor (B(2)R).

31 The bradykinin receptor B1R is overexpressed in many human c

32 efore explored the influence of lack of both bradykinin receptors (B1R and B2R) on diabetic nephropat

33 Coexpression of bradykinin receptor B2 (BKRB2), a Galphaq/11-coupled rec

34 However, bradykinin receptors became nearly as effective as M1 re

35 Bradykinin receptor blockade reversed the inhibitory eff

36 regulated dynorphin A (Dyn A) interacts with bradykinin receptors (BRs) in the spinal cord to promote

37 he authors report that the stimulation of B2 bradykinin receptors by bradykinin triggers the release

38 oser to helix 7 and helix 1 as compared with bradykinin-receptor complex models.

39 rat M(1)-muscarinic receptor, and human B(1)-bradykinin receptor did not alter the properties of the

40 (STIA) model, mice that lacked HK, pKal, or bradykinin receptors displayed protective phenotypes in

41 he known effect of oncogenic Ras to increase bradykinin receptor expression and the ability of PDGF t

42 lotting showed significant elevation of B(2)-bradykinin receptor expression in all normotensive anima

43 We have cloned and sequenced the human B1 bradykinin receptor gene (BDKRB1), which contains an uni

44 To determine the presence of bradykinin receptors in skeletal muscle, we examined in

45 Ca2+ sensor-1 were blocked, suggesting that bradykinin receptor-induced intracellular Ca2+ increases

46 We conclude that bradykinin receptors inhibit M current of sympathetic ne

47 The bradykinin receptor is a G protein-coupled receptor (GPC

48 This action of dynorphin at bradykinin receptors is distinct from the primary signal

49 es demonstrate that urothelial expression of bradykinin receptors is plastic and is altered by pathol

50 states of a single binding site, we examined bradykinin receptors on a pure skeletal muscle system, t

51 , which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells.

52 Thus, both the B1 and B2 bradykinin receptors play an important role in reducing

53 n mediated the enhancing action of purine or bradykinin receptor stimulation on eNOS Ser-635/633 phos

54 produce IL-12 through activation of the B(2) bradykinin receptor subtype and that bradykinin-induced

55 nvestigated the localization and function of bradykinin receptor subtypes B1 and B2 in the normal and

56 , we studied the human B2 (B2R) and B1 (B1R) bradykinin receptor subtypes in HEK293 cells.

57 To assess whether this represents multiple bradykinin receptor subtypes present in skeletal muscle

58 After activation of the B(2) bradykinin receptor, the electric field sensed by the dy

59 at have been reported to reside in caveolae, bradykinin receptor type 2 (B(2)R), which is coupled to

60 a signaling pathway initiated by the B2 type bradykinin receptor via G(q) activation, which leads to

61 t of the C-terminal domain of the human B(1)-bradykinin receptor with the C-terminal domains of eithe

62 is known about the cell types expressing the bradykinin receptor within the brain.